EUVIMEDEUVIMED entdecken
Crossref

Disrupting the Palbociclib‐Induced AKR1B10 ‐ PI3K / AKT / mTOR Axis by Everolimus Synergistically Suppresses Head and Neck Squamous Cell Carcinoma Progression

Mengyu Chen, Tao Zhu, Siyu Han, Tian Dai, Jiakuo Gu, Wenlu Wang, Yafang Chen, Juyan Zheng, Minghua Ge iD

The FASEB Journal · 30.11.2026 · 40 (22)

DOI: 10.1096/fj.202601169r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 17.11.2026. Verfasst von Mengyu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Piperazines, TOR Serine-Threonine Kinases, Everolimus, Pyridines. Die Arbeit nennt 31 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), | Medical and Health Research Project of Zhejiang Province (), National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) is frequently accompanied by amplification of the 11q13 region and inactivating mutations in CDKN2A , leading to abnormal CDK4/6 activation. Treatment with the CDK4/6 inhibitor palbociclib has demonstrated efficacy in HNSCC. However, monotherapy with palbociclib can induce compensatory activation of the PI3K/AKT/mTOR signaling pathway, leading to the development of acquired resistance. This study aimed to investigate the antitumor efficacy of the CDK4/6 inhibitor palbociclib combined with the mTOR inhibitor everolimus in HNSCC and to elucidate the potential molecular mechanism of their synergistic effect. We investigated the synergistic therapeutic effects of palbociclib and everolimus in HNSCC by using CCK‐8, EdU, scratch assay, transwell, flow cytometry, nude mouse xenograft and orthotopic tumor models. The potential molecular mechanisms of their synergistic effect were explored through RNA sequencing (RNA‐seq), real‐time quantitative PCR (RT‐qPCR), and western blotting. The results demonstrated that palbociclib and everolimus exhibit significant synergistic antitumor activity in HNSCC. In vitro experiments confirmed that combined administration significantly inhibits proliferation of HNSCC cell lines, blocks cell cycle progression, and induces apoptosis. In vivo xenograft models in nude mice showed that the combination therapy effectively suppresses tumor growth without inducing significant systemic toxicity. Mechanistic studies revealed that palbociclib monotherapy induces upregulation of AKR1B10 expression. In addition, AKR1B10 interacts with PI3K, leading to further activation of the PI3K/AKT/mTOR pathway. Everolimus could reverse this process by blocking the compensatory activation of the AKR1B10/PI3K/AKT/mTOR pathway, thus exerting a synergistic effect. The combination of palbociclib and everolimus exhibited significant synergistic antitumor activity in HNSCC. This study provides a novel combination therapy strategy for HNSCC with important clinical translational significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesTOR Serine-Threonine KinasesEverolimusPyridinesProto-Oncogene Proteins c-aktSquamous Cell Carcinoma of Head and NeckPhosphatidylinositol 3-KinasesHead and Neck NeoplasmsHumansAnimalsMiceMice, NudeSignal TransductionCell Line, TumorDrug SynergismXenograft Model Antitumor AssaysCell ProliferationMice, Inbred BALB CApoptosisMale

Stichwörter der Autor:innen

AKR1B10PI3K/AKT/mTOReverolimushead and neck squamous cell carcinomapalbociclibsynergistic effect

Substanzen

PiperazinespalbociclibTOR Serine-Threonine KinasesEverolimusPyridinesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, human

Autor:innen und Institutionen

  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
  • Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Zhejiang Provincial People's Hospital, Hangzhou, China.
  • Zhejiang Provincial Clinical Research Center for Head & Neck Cancer, Zhejiang Provincial People's Hospital, Hangzhou, China.
  • Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.

ORCID-Profile: Minghua Ge

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • | Medical and Health Research Project of Zhejiang Province ()
  • National Natural Science Foundation of China
  • Medical and Health Research Project of Zhejiang Province

Zitieren

APA

Chen, M., Zhu, T., Han, S., Dai, T., Gu, J., Wang, W., Chen, Y., Zheng, J., & Ge, M. (2026). Disrupting the Palbociclib‐Induced AKR1B10 ‐ PI3K / AKT / mTOR Axis by Everolimus Synergistically Suppresses Head and Neck Squamous Cell Carcinoma Progression. The FASEB Journal, 40(22). https://doi.org/10.1096/fj.202601169r

Vancouver

Chen M, Zhu T, Han S, Dai T, Gu J, Wang W, et al. Disrupting the Palbociclib‐Induced AKR1B10 ‐ PI3K / AKT / mTOR Axis by Everolimus Synergistically Suppresses Head and Neck Squamous Cell Carcinoma Progression. The FASEB Journal. 2026;40(22). doi:10.1096/fj.202601169r

BibTeX
@article{Chen2026,
  author = {Chen, Mengyu and Zhu, Tao and Han, Siyu and Dai, Tian and Gu, Jiakuo and Wang, Wenlu and Chen, Yafang and Zheng, Juyan and Ge, Minghua},
  title = {Disrupting the Palbociclib‐Induced AKR1B10 ‐ PI3K / AKT / mTOR Axis by Everolimus Synergistically Suppresses Head and Neck Squamous Cell Carcinoma Progression},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {22},
  doi = {10.1096/fj.202601169r}
}
Kostenlos starten →